View More View Less
  • 1 Szent Lázár Megyei Kórház, Salgótarján, Füleki út 54–56., 3100
  • 2 Bajcsy-Zsilinszky Kórház, Budapest
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Absztrakt

A sarcoma synoviale a lágyrész-sarcomák 5–10%-ában, az összes malignus daganatok 0,05–0,1%-ában fordul elő. Főként a végtagokon keletkezik, azonban bárhol kialakulhat. A betegek 50%-ában 3–5 éven belül metasztázisok jelennek meg (tüdő, nyirokcsomó, csont), sőt akár 20 év elteltével is számítani lehet a sarcoma synoviale kiújulására. Az 5 éves teljes túlélés lokalizált betegség esetén 76%, metasztatikus esetben 10%. Az életkor, daganatméret, szövettani altípus és a radioterápia megtörténte befolyásolja a prognózist. Az adjuváns kemoterápia szerepe nem bizonyított. Számos klinikai vizsgálat van folyamatban a lokálisan előrehaladott, relaptálódott/refrakter és metasztatikus sarcoma synoviale kezelésére. A sarcoma synoviale biológiai viselkedésének jobb megértésével a célzott kezelés és a konvencionális terápia kombinációja válhat a jövő útjává. Orv. Hetil., 2015, 156(22), 875–880.

  • 1

    Pack, G. T., Ariel, I. M.: Synovial sarcoma (malignant synovioma); a report of 60 cases. Surgery, 1950, 28(6), 1047–1084.

  • 2

    Singer, S., Demetri, G. D., Baldini, E. H., et al.: Management of soft-tissue sarcomas: an overview and update. Lancet Oncol., 2000, 1, 75–85.

  • 3

    Weiss, S. W., Goldblum, J. R., Folpe, A. R.: Einzinger and Weiss’s Soft Tissue Tumors. 4th edition. Mosby, Inc., Chicago, 2001.

  • 4

    Trassard, M., Le Doussal, V., Hacène, K., et al.: Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J. Clin. Oncol., 2001, 19(2), 525–534.

  • 5

    McCarville, M. B., Spunt, S. L., Skapek, S. X., et al.: Synovial sarcoma in pediatric patients. AJR, Am. J. Roentgenol., 2002, 179(3), 797–801.

  • 6

    Guillou, L., Benhattar, J., Bonichon, F., et al.: Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J. Clin. Oncol., 2004, 22(20), 4040–4050.

  • 7

    Spurell, E. L., Fisher, C., Thomas, J. M., et al.: Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann. Oncol., 2005, 16(3), 437–444.

  • 8

    Palmerini, E., Staals, E. L., Alberghini, M., et al.: Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer, 2009, 115(13), 2988–2998.

  • 9

    Italiano, A., Penel, N., Robin, Y. M., et al.: Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann. Oncol., 2009, 20(3), 425–430.

  • 10

    Krieg, A. H., Hefti, F., Speth, B. M., et al.: Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. Ann. Oncol., 2011, 22(2), 458–467. [Epub 2010 Aug 17]

  • 11

    Speth, B. M., Krieg, A. H., Kaelin, A., et al.: Synovial sarcoma in patients under 20 years of age: a multicenter study with a minimum follow-up of 10 years. J. Child. Orthop., 2011, 5(5), 335–342.

  • 12

    Wushou, A., Miao, X. C.: Tumor size predicts prognosis of head and neck synovial cell sarcoma. Oncol. Lett., 2015, 9(1), 381–386.

  • 13

    Balogh, Z., Szemlaky, Z., Szendroi, M., et al.: Correlation between DNA ploidy, metaphase high-resolution comparative genomic hybridization results and clinical outcome of synovial sarcoma. Diagn. Pathol., 2011, 6, 107.

  • 14

    Ladanyi, M., Antonescu, C. R., Leung, D. H., et al.: Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res., 2002, 62(1), 135–140.

  • 15

    Papanastassiou, I., Ioannou, M., Papagelopoulos, P. J., et al.: P53 expression as a prognostic marker in giant cell tumor of bone: a pilot study. Orthopedics, 2010, 33(5).

    • Crossref
    • Export Citation
  • 16

    Teng, H. W., Wang, H. W., Chen, W. M., et al.: Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. J. Surg. Oncol., 2011, 103(8), 773–781.

  • 17

    Chakiba, C., Lagarde, P., Pissaloux, D., et al.: Response to chemotherapy is not related to chromosome instability in synovial sarcoma. Ann. Oncol., 2014, 25(11), 2267–2271.

  • 18

    Suehara, Y., Tochigi, N., Kubota, D., et al.: Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J. Proteomics, 2011, 74(6), 829–842.

  • 19

    Song, S., Park, J., Kim, H. J., et al.: Effects of adjuvant radiotherapy in patients with synovial sarcoma. Am. J. Clin. Oncol., 2014 Oct 27. [Epub ahead of print]

  • 20

    Naing, K. W., Monjazeb, A. M., Li, C. S., et al.: Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis. J. Surg. Oncol., 2015, 111(2), 158–164.

  • 21

    Ferrari, A., De Salvo, G. L., Brennan, B., et al.: Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Ann Oncol., 2015, 26(3), 567–572.

  • 22

    Hu, X., Cai, H., Zhou, M., et al.: New clinical application of high-intensity focused ultrasound: local control of synovial sarcoma. World J. Surg. Oncol., 2013, 11, 265.

  • 23

    Schwindenhammer, B., Podleska, L. E., Kutritz, A., et al.: The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas. World J. Surg. Oncol., 2013, 11(1), 185.

  • 24

    Balieiro, M. A., Lopes, A. J., Costa, B. P., et al.: The surprising outcome of a giant primary mediastinal synovial sarcoma treated with neoadjuvant chemotherapy. J. Thorac. Dis., 2013, 5(1), 94–96.

  • 25

    Stanelle, E. J., Christison-Lagay, E. R., Wolden, S. L., et al.: Pulmonary metastasectomy in pediatric/adolescent patients with synovial sarcoma: an institutional review. J. Pediatr. Surg., 2013, 48(4), 757–763.

  • 26

    Gerber, N. K., Meyers, P. A., LaQuaglia, M. P., et al.: Whole-lung irradiation in the treatment of metastatic synovial sarcoma. Pediatr. Blood Cancer, 2014, 61(11), 2092–2093.

  • 27

    Yetisyigit, T., Arpaci, E., Seber, E. S., et al.: Salvage treatment experience in advanced synovial sarcoma: a multicenter retrospective analysis of the Anatolian Society of Medical Oncology. Asian Pac. J. Cancer Prev., 2013, 14(9), 5185–5188.

  • 28

    Minchom, A., Jones, R. L., Fisher, C., et al.: Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma, 2010, 2010, Article ID 264360.

  • 29

    Abe, K., Maebayashi, T., Shizukuishi, T., et al.: Radiological assessment following thermoradiation therapy for primary pleural synovial sarcoma: case report. Med. Oncol., 2010, 27(3), 1027–1030.

  • 30

    Zanardi, E., Maruzzo, M., Montesco, M. C., et al.: Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases. Anticancer Drugs, 2014, 25(10), 1227–1230.

  • 31

    Jones, K. B., Haldar, M., Schiffman, J. D., et al.: Of mice and men: opportunities to use genetically engineered mouse models of synovial sarcoma for preclinical cancer therapeutic evaluation. Cancer Control, 2011, 18(3), 196–203.

  • 32

    Liu, L., Cao, Y., Chen, C., et al.: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res., 2006, 66(24), 11851–11858.

  • 33

    Maki, R. G., D’Adamo, D. R., Keohan, M. L., et al.: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol., 2009, 27(19), 3133–3140.

  • 34

    Kasper, B., Sleijfer, S., Litière, S., et al.: Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann. Oncol., 2014, 25(3), 719–724.

  • 35

    Asmane, I., Watkin, E., Alberti, L., et al.: Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur. J. Cancer, 2012, 48(16), 3027–3035.

  • 36

    Weigel, B., Malempati, S., Reid, J. M., et al.: Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr. Blood Cancer, 2014, 61(3), 452–456.

  • 37

    Pappo, A. S., Patel, S. R., Crowley, J., et al.: R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. Clin. Oncol., 2011, 29(34), 4541–4547.

  • 38

    Ito, T., Ouchida, M., Morimoto, Y., et al.: Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett., 2005, 224(2), 311–319.

  • 39

    Cassier, P. A., Lefranc, A., Amela, E. Y., et al.: A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br. J. Cancer, 2013, 109(4), 909–914.

  • 40

    Chugh, R., Wathen, J. K., Maki, R. G., et al.: Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J. Clin. Oncol., 2009, 27(19), 3148–3153.

  • 41

    Heinrich, M. C., Joensuu, H., Demetri, G. D., et al.: Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin. Cancer Res., 2008, 14(9), 2717–2725.

  • 42

    Thornton, K. A., Chen, A. R., Trucco, M. M., et al.: A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int. J. Cancer, 2013, 133(4), 997–1005.

  • 43

    Numoto, K., Yoshida, A., Sugihara, S., et al.: Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2’-deoxycytidine against synovial sarcoma cell lines. J. Cancer Res. Clin. Oncol., 2010, 136(1), 17–25.

  • 44

    Schildhaus, H. U., Riegel, R., Hartmann, W., et al.: Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors. Hum. Pathol., 2011, 42(11), 1667–1675.

  • 45

    Sakai, T., Eskander, R. N., Guo, Y., et al.: Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines. Orthop. Res., 2012, 30(7), 1045–1050.

  • 46

    Sun, Y., Wang, H., Lin, F., et al.: Inhibition of proliferation and gene expression regulation by (-)-epigallocatechin-3-gallate in human synovial sarcoma cells. Med. Oncol., 2011, 28(4), 1463–1468.

  • 47

    Takenaka, S., Naka, N., Araki, N., et al.: Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. Int. J. Oncol., 2010, 36(4), 823–831.

  • 48

    Wakamatsu, T., Naka, N., Sasagawa, S., et al.: Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma. Cancer Sci., 2014, 105(9), 1124–1134.

  • 49

    Nielsen, T. O., Poulin, N. M., Ladanyi, M.: Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. Cancer Discov., 2015, 5(2), 124–134.

 

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

 

Mendeley citation style is available HERE.
  • Impact Factor (2019): 0.497
  • Scimago Journal Rank (2018): 0.176
  • SJR Hirsch-Index (2018): 20
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)
  • Impact Factor (2018): 0.564
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu